Macrophage migration inhibitory factor (MIF) has been linked to fundamental processes such as control of cell proliferation, cell survival, angiogenesis, and tumor progression. The expression of MIF has been reported in several tumors. However, the precise role of MIF in tumor cells remains unclear. In the present study, we investigated the expression pattern and the function of MIF in neuroblastoma. Our results showed that intracellular MIF was upregulated in neuroblastoma tumor tissues and cell lines. MIF protein expression significantly correlated with the grade of tumor differentiation. In addition, we found that MIF induced a significant dosedependent increase of vascular endothelial growth factor and interleukin-8 secretion. We also observed that an increased MIF expression level correlated with N-Myc protein (the N-myc oncogene product) expression in neuroblastoma tissues. MIF increased the expression of N-myc mRNA and N-Myc protein and induced N-Myc translocation from the cytoplasm to nucleus in neuroblastoma cell lines. MIF-induced N-Myc expression was found to be dependent on ERK signaling pathways. The inhibition of ERK activation reduced MIF-mediated NMyc expression. These results suggest that MIF may contribute to the progression of neuroblastoma by (a) inducing N-Myc expression and (b) upregulating the expression of angiogenic factors.
Introduction
Neuroblastoma is the second most common pediatric solid cancer, and is responsible for approximately 15% of all childhood cancer deaths (Maris and . The clinical hallmark of neuroblastoma is marked heterogeneity, and tumor progression is likely to vary widely according to the stage, age at diagnosis, and anatomical site. Generally, infants less than 1 year of age with neuroblastoma can often be cured (Pritchard and Hickman, 1994) . However, children who are over 1 year of age at clinical presentation often have metastatic disease that is unresponsive to even the most aggressive surgical and medical intervention regimens. The biological mechanisms governing the unusual behavior of this tumor have yet to be elucidated.
The biological hallmark of neuroblastomas is the complexity of the genetic abnormalities acquired by the tumor cells. Some of these abnormalities are powerful prognostic markers that are independent of the clinical features. These genetic aberrations are ploidy changes, deletions of chromosome arms 1p and 11q, gains of chromosome arm 17q, and amplification of the N-myc oncogene (Bown, 2001) . N-myc amplification leads to high concentrations of the gene product, a nuclear phosphoprotein (N-Myc). The differentiation is often accompanied by a reduction in N-myc expression (Brodeur et al., 1984) . This is likely to be a crucial event, since forced expression of N-myc in non-N-mycamplified neuroblastoma cells blocks their differentiation and enhances their proliferative potential. In comparison, reduced N-myc expression correlates with growth inhibition in N-myc-amplified neuroblastoma cells (Brodeur et al., 1984; Seeger et al., 1985; Brodeur and Nakagawara, 1992) .
Tumor growth and metastasis depend on the ability of the tumor to induce its own blood supply. This process is dependent on the induction of angiogenesis mediated by the release of angiogenic factors secreted by the tumor cells. Tumor cells secrete a wide variety of angiogenic factors that participate in the development of microvasculature in the tumor (Fidler and Ellis, 1994; Carmeliet and Jain, 2000) . Among the identified angiogenic factors, vascular endothelial growth factor (VEGF) and are the most potent and representative (Smith et al., 1994; Dvorak et al., 1995; Desbaillets et al., 1997; Karkkainen and Petrova, 2000) . Other angiogenic factors such as basic fibroblast growth factor, angiopoietin-1 (Ang-1) and Ang 2, and TGF-a have also been shown to induce angiogenesis in vitro and in vivo (Folkman and Klagsbrun, 1987; Gille, Swerlick and Caughman, 1997) . Furthermore, high expression of these factors was strongly correlated with advanced stage in neuroblastoma (Eggert et al., 2000) . VEGF is present in a variety of human tumors, including lung (Mattern et al., 1996) , breast , gastrointestinal (Brown et al., 1993) , and neuroblastoma tumors (Rossler et al., 1999) . IL-8 is expressed by a number of human malignancies, and its expression correlates with the metastatic potential of tumors (Koch et al., 1992; Singh et al., 1994) . It has been reported that IL-8 produced by neuroblastoma is a factor in angiogenesis (Ferrer et al., 2000) . Understanding the angiogenic factors and regulatory cascade promoting angiogenesis in neuroblastoma may lead to the development of effective antiangiogenic strategies.
Macrophage migration inhibitory factor (MIF) was originally found to be produced by activated lymphocytes (David, 1966) . MIF has emerged to play a central role in the control of the host inflammatory and immune responses. In addition to MIFs' potent effects on the immune system, several reports have linked MIF to fundamental processes controlling cell proliferation, cell survival, angiogenesis, and tumor progression (Mitchell and Bucala, 2000) . Recently, the upregulation of MIF was found in human melanomas (Shimizu et al., 1999) , breast carcinomas (Bini et al., 1997) , metastatic prostate cancers (Meyer-Siegler and Hudson, 1996) , adenocarcinomas of the lung (Kamimura et al., 2000) , and hepatocellular carcinomas (Akbar et al., 2001; Ren et al., 2003) . However, the precise role of MIF in tumorigenesis remains unclear.
The purpose of this study was to determine and provide evidence for the causal role of MIF in the development of neuroblastoma. Our results suggest that MIF is upregulated in poorly differentiated neuroblastomas. MIF plays a role in tumor progression by increasing the N-Myc expression and upregulating the expression of angiogenic factors by tumor cells.
Results

Expression of MIF in neuroblastoma tissues
The hematoxylin-eosin (H&E) staining technique allows specimens to be identified as either tumorous or nontumorous. The grade of differentiation of tumors could be easily identified by standard histopathological criteria. The typical neuroblastoma is composed of undifferentiated small cells with dark-stained nuclei and scanty cytoplasm (Figure 1a ). In contrast, the welldifferentiated neuroblastoma or ganglioneuroblastoma is mixed with a small number of undifferentiated small cells and large differentiated neuroblastoma cells, which look like mature ganglion cells. Figure 1b shows the histological feature of ganglioneuroma, in which almost all tumor cells are ganglion-like tumor cells. Using immunohistochemical staining, MIF expression was found in all specimens of neuroblastoma. Figure 1c shows that poorly differentiated neuroblastoma cells expressed MIF protein strongly, while well-differentiated tumor cells were weakly positive in MIF expression (Figure 1d ). Overall, MIF expression was seen in the cytoplasm of poorly differentiated tumor cells in all cases, while it was negative or weakly positive in the better differentiated neuroblastoma cells. Furthermore, MIF protein expression significantly correlated with the grade of tumor differentiation (P ¼ 0.038). MIF protein expression was also observed in vessel endothelia and some infiltrating cells in nontumor regions (data not shown).
In addition, we conducted an immunohistochemical analysis for the protein N-Myc in 32 patients with primary neuroblastoma. N-Myc expression showed a pattern of nuclear staining in the neuroblastoma cells (Figure 1e (Figure 3b ). These results suggested that MIF was unable to increase the expression of N-myc and N-Myc if the tumor cells were constitutively N-Myc positive, but could increase de nove N-Myc expression in SK-N-SH. In addition, TCM (MIF concentrations more than 100 ng/ml) could also increase N-Myc expression by SK-N-SH cells, and this enhanced N-Myc expression could be inhibited by anti-MIF neutralizing monoclonal antibodies (mAbs) in a dose-dependent manner, while control mAb had no effect ( Figure 3c ). Furthermore, cytoplasmic N-Myc disappeared after MIF treatment for 24 h, while nuclear N-Myc was increased (Figure 3d ).
MIF-induced mitogen-activated protein kinases (MAPK) in human neuroblastoma cells
Since the MAPK pathway cascade is an important signaling pathway that is activated by various growth factors, we evaluated the time dependence of MIFinduced MAPK activity in neuroblastoma cell line. The phospho-specific p42/44 MAPKs antibody was used to determine MIF-induced tyrosine phosphorylation of these molecules in SK-N-SH. Western blot analysis demonstrated that MIF at 100 ng/ml rapidly 
MAPKs inhibitor downregulates N-Myc expression
To determine whether MAPK activation played a role in MIF-induced N-Myc expression, cells were pretreated with MEK1 inhibitor PD98059 for 30 min before MIF stimulation. As shown in Figure 4b , pretreatment with PD98059 impaired MIF-induced p42/44 MAPK phosphorylation. Consequently, MIF-induced N-Myc expression was inhibited by PD98059 in a dose-dependent manner (Figure 4c ).
MIF stimulated VEGF and IL-8 secretion in neuroblastoma cell culture supernatants
To detect whether MIF contributes to the production of VEGF and IL-8 by neuroblastoma cells, SK-N-SH and SK-N-DZ were stimulated with MIF for 24 h. IL-8 and VEGF in the supernatants of cultured cell lines were measured by ELISA. MIF at concentrations up to 100 ng/ml in cells induced a significant increase of IL-8 and VEGF secretion in a dose-dependent manner ( Figure 5 ). In order to study whether endogenous MIF expressed by tumor cells is sufficient to induce the production of IL-8 and VEGF, SK-N-DZ and SK-N-SH cells (5 Â 10 5 cells/well) were cultured in 24-well plates for a longer period (48 h) in the presence of 5% FBS with anti-MIF neutralizing mAb (100 mg/ml) or isotype control mAb (100 mg/ml). The production of IL-8 and VEGF could be inhibited by neutralizing MIF mAb, but not by control mAb (Figure 6 ).
Discussion
Our results demonstrate that human neuroblastomas expresses large amounts of MIF, suggesting an important role for MIF in neuroblastoma development. Several studies have demonstrated upexpression and enhanced production of MIF by tumor cells (MeyerSiegler and Hudson, 1996; Shimizu et al., 1999; Kamimura et al., 2000; Akbar et al., 2001) . It has been reported recently that human and murine neuroblastoma cell lines secrete MIF (Bin et al., 2002) . However, the expression of MIF in human neuroblastoma specimens has not been studied, and it is still unclear as to how MIF is involved in tumorigenesis, especially in promoting tumor angiogenesis and metastasis. Our results first show that the expression of MIF is correlated significantly with the grade of tumor differentiation and NMyc expression. Moreover, MIF stimulates the angiogenic factors VEGF and IL-8 secretion by tumor cell lines.
N-myc gene amplification is one of the most important and independent prognostic factors in neuroblastoma (Seeger et al., 1985) . N-myc amplification is associated with advanced disease stage, rapid tumor progression, and poor prognosis (Seeger et al., 1985 (Seeger et al., , 1988 . Concentrations of the N-Myc protein are generally high in tumors showing amplification of the gene, but may also be increased in N-myc single copy disease (Bown, 2001) . N-myc is associated with tumorigenesis and cell proliferation (Chambery et al., 1999) . Furthermore, it has been reported that poorly differentiated neuroblastoma is an aggressive and invasive tumor, often amplified for the N-myc oncogene, and resulting in unfavorable prognosis (Brodeur et al., 1984) . Recent evidence suggests that the activation of N-Myc protein in neuroblastoma causes an increase in the retinoblastoma protein inhibitor, Id2, leading to cell cycle progression (Lasorella et al., 2000) . However, the molecules that could mediate the expression and activation of N-myc and N-Myc protein in neuroblastoma remain unknown, although recent studies have determined that insulin-like growth factor I and interferon-g were able to stimulate N-Myc expression (Wada Misawa et al., 2000) . In our study, we observed that neuroblastoma cells expressed nuclear NMyc, and N-Myc correlated with the MIF expression in tumor tissues. Therefore, we hypothesized that MIF may be an inducer of N-Myc expression. To test this hypothesis, we demonstrated by using RT-PCR and Western blot, respectively, that exogenous MIF could stimulate the expression of both N-myc mRNA and NMyc protein in neuroblastoma cell. Furthermore, endogenous MIF expressed by tumor cell lines could increase N-Myc expression and the enhanced effect could be inhibited by anti-MIF neutralizing antibody. Our results also showed that cytoplasmic N-Myc disappeared and nuclear N-Myc was increased in tumor cells treated with MIF for 24 h, suggesting that MIF might enhance the N-Myc nuclear translocation or increase the production of nuclear N-Myc. It has been reported that only nuclear N-Myc can dimerize to a nuclear protein Max and then activate transcription of an as yet undefined series of growth-promoting genes (Maris and Matthay, 1999). We provided evidence for an additional novel mechanism by which MIF promotes malignant development in neuroblastoma, namely its ability to induce the expression of N-Myc. The hypothesis that MIF could activate N-Myc by promoting nuclear localization of N-Myc is attractive, but further studies will be required to test this. Mitchell and Bucala (2000) reported that the p44/p42 MAPK is involved in MIF-induced proliferation of fibroblasts. The ERK MAP kinase pathway of activation results in the phosphorylation and activation of a number of cytosolic proteins such as P90 rsk , c-myc, and cytoplasmic phospholipase A2. The role of MAPK activation in MIF-mediated N-Myc expression has not been studied. In this study, we found that MAPK was markedly activated by MIF stimulation in neuroblastoma cells, and that inhibitor PD98059 suppressed MIFmediated N-Myc expression. This suggests that the MAPK pathway is required for MIF-induced N-Myc It has been reported that MIF can exert a role in tumorigenesis, functionally inactivating the tumor suppressor protein p53 (Hudson et al., 1999) . Moreover, it has been shown that p53 accumulation in neuroblastoma, in the absence of mutation, is associated with functional inactivation, which interferes with the downstream mediators of p53 function (Tweddle et al., 2001) . Our results suggested that upregulation of MIF in neuroblastoma may contribute to p53 inactivation, promoting tumorigenesis and chemoresistance. However, further studies are required to confirm this hypothesis.
Angiogenesis is a critical process in the development and metastasis of many solid tumors, including neuroblastoma. It has been reported that the vascularity of neuroblastoma in patients with widely metastatic disease is significantly higher than that in patients with local or regional disease, and that vascularity shows a strong inverse correlation with survival of patients (Meitar et al., 1996) . One of the important activities of MIF in promoting tumorigenesis and metastasis is to stimulate angiogenesis (Ogawa et al., 2000) . It has been reported that immunoneutralization of MIF during the initial stage of lymphoma growth had profound effects on tumor size (Chesney et al., 1999) . This effect was not due to the inhibition of tumor cell proliferation but rather to the inhibition of endothelial cell growth. It was subsequently shown that MIF was a required factor for tumor-initiated endothelial cell proliferation (Yang et al., 2000) and, ultimately, tumor neovascularization. These facts provide the evidence that MIF may function to stimulate tumor-associated angiogenesis by exerting a direct effect on endothelial growth. However, the role of MIF in angiogenesis involving tumor and endothelial cells is less well understood.
The angiogenic factors VEGF and IL-8 can be considered, respectively, as a growth factor and an IL specific to neovascularization. It has been reported that neuroblastoma cell lines and tumor tissues expressed /well) for 48 h in the presence of 5% FBS with anti-MIF neutralizing mAb (100 mg/ml) or isotype control mAb (100 mg/ml). The culture supernatants were collected and IL-8 and VEGF were measured by ELISA (mean7s.d., n ¼ 3). *Po0.05 high levels of VEGF, and that anti-VEGF antibody prevented growth increment of endothelial cells (Meister et al., 1999; Langer et al., 2000) . In addition, amplification of N-myc is associated with enhanced angiogenesis of human neuroblastoma (Meitar et al., 1996) . Recently, it has been reported that enhanced expression of N-myc in human neuroblastoma cells downregulated an inhibitor of endothelial cell proliferation, activin A, suggesting that the N-myc-induced downregulation of activin could contribute to tumor angiogenesis (Breit et al., 2000) . However, the effects of MIF on the expression of angiogenic factors by neuroblastoma have not been reported previously. In our study, not only exogenous MIF but also endogenous MIF secreted by tumor cells were able to stimulate VEGF and IL-8 secretion in neuroblastoma cell lines in vitro. Furthermore, anti-MIF neutralizing mAb can block the production of IL-8 and VEGF by tumor cells. We found that MIF was not able to stimulate tumor cells proliferation (data not shown), but we provided evidence for an additional novel mechanism by which MIF promotes angiogenesis, namely, its ability to induce the expression of angiogenic factors N-Myc, IL-8, and VEGF by tumor cell lines. Therefore, MIFinduced upregulation of N-Myc, VEGF, and IL-8 by neuroblastoma cells may contribute to tumor angiogenesis. It would be worth studying whether blocking the MIF expression would benefit tumor control in neuroblastoma by inhibiting angiogenesis. Interestingly, there were differences in the levels of IL-8 and VEGF expressed by cell lines in response to MIF. One possibility may be that the differences in membrane receptor on surface in tumor cells led to different responses to MIF. There is very little evidence to explain how MIF interacts with cells, although CD74 has been reported to be a membrane-bound receptor for MIF recently (Leng et al., 2003) . It would be a very worthwhile endeavor to study cell-based models and pathways that are sensitive to MIF stimulation, in order to elucidate the mechanisms by which MIF exerts its effects from the cell surface.
In summary, this study demonstrates that neuroblastoma expresses a high level of MIF. MIF is able to promote the expression of N-Myc, IL-8, and VEGF in neuroblastoma cell lines. Targeting the MIF/MAPK pathway may be a useful therapeutic approach in the management of N-myc-amplified neuroblastoma.
Materials and methods
Reagents
All reagents were obtained from Sigma (St Louis, MO, USA) unless otherwise stated. Mouse monoclonal anti-pan ERK was from Becton Dickinson (Bedford, MA, USA); PD98059, a mouse monoclonal anti-phospho-ERK (p42/44), and goat anti-b-actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); and a mouse monoclonal anti-N-Myc was purchased from Oncogene (Boston, MA, USA). Peroxidaseconjugated goat anti-mouse IgG and mouse peroxidase antiperoxidase complexes (PAP) obtained from Dako (Glostrup, Demark). Tissue culture plastic was purchased from Corning (Coming, NY, USA). Dulbecco's modified Eagles's minimum essential medium (DMEM) , fetal bovine serum (FBS) and antibiotics were from Gibco (Grand Island, NY, USA).
Tissue samples
Tumor specimens were obtained from 32 patients with surgically resected primary neuroblastoma treated between 1990 to 2000, in Queen Mary Hospital, Hong Kong. The patients included 25 males and seven females, and their median age at diagnosis was 60 months (range, 7.2-240 months). The grade of tumor differentiation was performed in accordance with International Neuroblastoma Pathology Classification (Shimada et al., 1999) . Representative blocks from both tumorous and nontumorous tissues from each specimen were taken for immunohistochemical study.
Immunohistochemical staining
Immunohistochemical staining using mAbs to MIF and NMyc was performed as described previously (Ren et al., 2003) . Paraffin sections were incubated with primary mAbs overnight at 41C. Sections were then washed with phosphate-buffered saline (PBS) (pH 7.4). Endogenous peroxidase was inactivated with 3% H 2 O 2 in methanol, and then incubated with peroxidase-conjugated goat anti-mouse IgG. After being washed with PBS, the sections were incubated with PAP and developed with 3,3-diaminobezidine to produce a brown color.
Cell culture and stimulation assay
Two human neuroblastoma cell lines (SK-N-SH and SK-N-DZ) were maintained in DMEM supplemented with 10% FBS and antibiotics. Cell lines in 24-well plates at 5 Â 10 5 /ml per well were cultured for 48 h in the presence of 10% FBS and the supernatants were collected as TCM. For stimulation experiments, cells were first seeded at 5 Â 10 4 /ml per well in 24-well plates and then incubated in DMEM with 10% FBS for 24 h. Cells were then washed with PBS and treated with different concentrations of recombinant human MIF or TCM with or without additional anti-MIF neutralizing mAb for 24 h. The culture supernatants of tumor cells were collected after each experiment and centrifuged at 1000 r.p.m. for 5 min to remove cells and debris. MIF, IL-8, and VEGF in the supernatants of cultured cell lines were measured by ELISA in accordance with the manufacturer's instructions.
Flow cytometric analysis
Cell surface expression of MIF and by tumor cell lines was evaluated by immunofluorescence staining with anti-MIF. After incubation for 45 min at 41C followed by washing with PBS, cells were either fixed in 1% paraformaldehyde/PBS or resuspended in PBS containing 0.5% propidium iodide in order to exclude dead cells. Labeled cells were assayed by a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA).
Intracellular MIF expression was evaluated following cell membrane staining. Cells were fixed in 4% paraformaldehyde/ PBS for 10 min. This was followed by treatment with 1% saponin for 20 min at room temperature. The treated cells were incubated with primary anti-MIF mAbs and FITC-conjugated secondary mAb, both for 45 min at 201C. After a final wash, cells were resuspended in 1% paraformaldehyde/PBS. Analysis of expression of MIF and N-Myc was performed with FACScan.
Reverse transcription polymerase-chain reaction
Cells were treated with MIF at 100 ng/ml for 24 h. Total cellular RNA was extracted with Trizol (Life Technologies, Inc., Gaithersburg, MD, USA), and RT was performed using a Ready To Go T-primed first-stand synthesis kit (Amersham Pharmacia Biotech., Amersham, UK). The primers for N-myc were 5 0 -CAT CCA CCA GCA GCA CAA CTA TG-3 0 (sense) and 5 0 -CCA GAG GCT CCC AAC CGT CAC-3 0 (antisense). The expression of b-actin mRNA was assayed as an internal control. Both sets of primers (N-myc and b-actin) were used together in one triplex reaction. The PCR conditions consisted of denaturation at 941C for 4 min and 35 cycles of amplification (30 s at 941C, 30 s at 621C, and 1 min at 701C) followed by extension at 701C for 5 min. The PCR products were separated on 1% agarose gel and stained with ethidium bromide.
Western blot
Cells were washed with PBS and directly lysed in RIPA buffer (0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40, and PBS) with PMSF and proteases inhibitors. Nuclear and cytoplasmic proteins from cells were isolated as described previously (Beryckere and Gannon, 1994) . The protein concentration was determined by the BioRad DC assay (Bio-Rad, Hercules, CA, USA). The samples were adjusted to equal protein concentrations and subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins on the gel were transferred onto nitrocellulose membranes that were blocked with 5% BSA in Tris-buffered saline containing 0.1% Tween 20 for 1 h at room temperature. Afterwards, the membranes were incubated with the indicated primary antibodies overnight at 41C. After being washed with PBS, the membranes were incubated with the appropriate secondary antibody. The immunoreactive bands were visualized with chemioluminescence (ECL, Amersham, UK).
Statistical analysis
All statistical analyses were performed using the computer software Statistical Package for Social Sciences 10.0 (SPSS Inc., Chicago, IL, USA). The w 2 test was used to examine the association between MIF expression and the grade of differentiation of neuroblastoma. Pearson's correlation was used to analyse the correlation between MIF and N-Myc expression. Differences were considered significant when the P-value was less than 0.05. Data are presented as mean7s.d.
